Effect of Intragastric Balloons on Liver Enzymes: A Systematic Review and Meta-Analysis
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Background Intragastric balloons (IGBs) are safe and effective in inducing weight loss in obese patients. The objective of this study was to review and analyze the available data of the effect of IGB on markers of nonalcoholic fatty liver disease (NAFLD) and liver enzymes. Methods Searches were performed of MEDLINE and Embase databases from inception through January 2016. Study inclusion criteria were the following: ≥5 overweight or obese adult patients undergoing intragastric balloon placement, with liver tests [alanine aminotransferase (ALT) or gamma-glutamyl transpeptidase (GGT)] or markers of NAFLD (e.g., imaging, biopsy) reported before balloon insertion and after balloon removal at 6 months. Results Nine observational studies and one randomized trial were identified. ALT decreased by -10.02 U/l (95 % CI, -13.2, -6.8), GGT decreased by -9.82 U/l (95 % CI, -12.9, -6.8), and BMI decreased by -4.98 kg/m(2) (-5.6, -4.4) with IGB therapy. Hepatic steatosis improved from baseline after 6 months of balloon therapy by magnetic resonance imaging (fat fraction, 16.7 ± 10.9-7.6 ± 9.8, p = 0.003), ultrasound (severe liver steatosis, 52-4 %, p Conclusion The use of intragastric balloon decreases liver enzymes and is potentially an effective short-term treatment for NAFLD as part of a multidisciplinary approach. Larger, more rigorous trials are needed to confirm the effect of IGBs on NAFLD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a reduction in NAS scores from 4 ± 2.25 to 2 ± 0.75 (p = 0.03) within six months [72].”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [72]
In the citing paper
“a cohort study employing magnetic resonance elastography and liver biopsies found an 87% patient cohort experienced a median NAS reduction of three points, with 73% achieving reductions of at least two points [73].”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [72]
In the citing paper
“Complementary evidence from a systematic review highlighted a significant histological improvement, demonstrating a reduction in NAS scores from 4 ± 2.25 to 2 ± 0.75 (p = 0.03) within six months [72].”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [72]
In the citing paper
“studies utilizing ultrasound and MRI observed hepatic fat fraction reductions from 16.7 ± 10.9 to 7.6 ± 9.8 (p = 0.003) [72].”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [72]
Citations
Cites
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
The global obesity pandemic: shaped by global drivers and local environments
Swinburn, B. A., Sacks, G., Hall, K. D., McPherson, K., Finegood, D. T., Moodie, M. L., & Gortmaker, S. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60813-1 · Cited by 4,888
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Chang, S.-H., Stoll, C. R. T., Song, J., Varela, J. E., Eagon, C. J., & Colditz, G. A. (2014) · JAMA Surgery · doi:10.1001/jamasurg.2013.3654 · Cited by 1,688
Nonalcoholic fatty liver disease
Adams, L. A. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.045232 · Cited by 1,610
Obesity in Adulthood and Its Consequences for Life Expectancy: A Life-Table Analysis
Peeters, A., Barendregt, J. J., Willekens, F., Mackenbach, J. P., Mamun, A. A., Bonneux, L., & and for NEDCOM, T. N. E. A. D. C. O. M. R. G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00008 · Cited by 1,479
Updated definitions of healthy ranges for serum alanine aminotransferase levels
Prati, D., Taioli, E., Zanella, A., Torre, E. D., Butelli, S., Del Vecchio, E., Vianello, L., Zanuso, F., Mozzi, F., Milani, S., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00006 · Cited by 1,445
Cited by
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
Polyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.014 · Cited by 1,211
“Another meta-analysis, specific for intragastric balloons, showed decrease in LFTs, steatosis and NAS six months post-surgery [201].”
BackgroundYanai, H., Adachi, H., Hakoshima, M., Iida, S., & Katsuyama, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015473 · Cited by 194
“To review and analyze the available data of the effect of intragastric balloons on markers of MASLD and liver enzymes, a meta-analysis was performed [78].”
MethodJirapinyo, P., McCarty, T. R., Dolan, R. D., Shah, R., & Thompson, C. C. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.03.017 · Cited by 86
Self-citationJagtap, N., Kalapala, R., Katakwar, A., Sharma, M., Aslam, M., Gupta, R., Rao, P. N., Goud, R., Tandan, M., Kanakagiri, H., et al. (2021) · Indian Journal of Gastroenterology · doi:10.1007/s12664-021-01202-7 · Cited by 43
“Though more rigorous trials are needed to confirm the effects of various endoscopic interventions, they can be considered for weight loss in NAFLD if lifestyle interventions fail [37].”
BackgroundXu, L., Jiang, C. Q., Lam, T. H., Zhang, W. S., Zhu, F., Jin, Y. L., Thomas, G. N., Cheng, K. K., & Schooling, C. M. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw396 · Cited by 34
“adiposity (23) or lipids (24)) were also associated with ALT, further MR studies using functionally related loci are helpful in addressing the potential issue of reverse causation (i.”
Background
Metadata
- Authors
- Popov, V. B., Thompson, C. C., Kumar, N., Ciarleglio, M. M., Deng, Y., & Laine, L.
- Affiliations
- VA NY Harbor Healthcare System (US)
- Brigham and Women's Hospital (US)
- Yale University (US)
- Corresponding author
- Popov, Violeta B.
- ORCID
- Venue
- Digestive Diseases and Sciences
- Published
- 2016-05-20
- Volume
- 61
- Issue
- 9
- Pages
- 2477-2487
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2406248787
- Cited by
- 43
- References
- 54
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 7 · 2023: 5 · 2022: 3 · 2021: 12 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 2 · 2016: 2
- FWCI
- 0.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DK34989)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- intragastric balloon, non-alcoholic fatty liver disease, liver enzymes, alanine aminotransferase, gamma-glutamyl transferase, hepatic steatosis, obesity, weight loss, NAFLD activity score
- MeSH terms
- Alanine Transaminase, gamma-Glutamyltransferase, Humans, Liver, Obesity, Ultrasonography, Weight Loss, Gastric Balloon, Treatment Outcome, Bariatric Surgery, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Intragastric Balloons on Liver Enzymes: A Systematic Review and Meta-Analysis. https://app.cochat.ai/papers/10.1007/s10620-016-4178-2
- The paper
- Popov, V. B., Thompson, C. C., Kumar, N., Ciarleglio, M. M., Deng, Y., & Laine, L. (2016). Effect of Intragastric Balloons on Liver Enzymes: A Systematic Review and Meta-Analysis. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-016-4178-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.